FDA Gives Estrogen-Androgen Drug Review Another Six-Month Reprieve
Published Date: 10/30/2026
Notice
Summary
The FDA is giving itself six more months—until May 4, 2027—to finish reviewing certain estrogen-androgen combination drugs. This extension affects drug makers and patients waiting on final decisions about these medicines’ effectiveness. No new costs or changes in drug availability are expected during this extra review time.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA found products lack evidence of effectiveness
The FDA's May 27, 2026, notice concluded that estrogen-androgen fixed‑combination drug products lack substantial evidence of effectiveness for treating moderate to severe vasomotor symptoms associated with menopause in patients not improved by estrogen alone. That May 2026 notice stated that shipment in interstate commerce of any identified product or any identical, related, or similar product not covered by an approved NDA or ANDA would be unlawful as of June 26, 2026.
Six‑month extension of DESI 7661
The FDA extended the effective date of its May 27, 2026, final resolution for estrogen-androgen fixed‑combination drugs by six months, moving the effective date to May 4, 2027. The extension gives the Agency more time to consider issues raised by interested parties, and the notice states that no new costs or changes in drug availability are expected during this extra review time.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22173, Privacy Act of 1974; System of Records
The Social Security Administration is launching a new system called the Client Data System to keep customer info organized and consistent across their programs. This change helps SSA serve people faster and better by having all key data in one place. The system starts now, but some new rules kick in November 30, 2026, and the public can comment until then—no extra costs involved!
Next: 2026-22177, Surety Bond Guarantee Program Fees
Starting November 30, 2026, the SBA is changing the fees for its Surety Bond Guarantee Program, which helps small contractors get bonding when they can’t get it elsewhere. These fee changes affect surety companies and small businesses (except manufacturing projects) and help keep the program strong and ready to support more small businesses. If you’re involved in this program, get ready for updated fees that keep the support flowing!